MARKET

CYYNF

CYYNF

Cynata Therapeut
OTCPK
0.150
NaN%
Closed 09:30 02/13 EST
OPEN
--
PREV CLOSE
0.150
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.150
52 WEEK LOW
0.150
MARKET CAP
35.62M
P/E (TTM)
-4.9834
1D
5D
1M
3M
1Y
5Y
1D
Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders
TipRanks · 02/03 22:55
Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance
TipRanks · 01/29 00:48
Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline
TipRanks · 01/23 06:58
Cynata Completes Enrollment in Phase 2 aGvHD Trial
TipRanks · 12/14/2025 23:37
Cynata’s CYP-001 Therapy Shows Promise in Kidney Transplant Trial
TipRanks · 12/03/2025 22:58
Cynata Therapeutics Updates Director’s Securities Holdings
TipRanks · 11/30/2025 23:37
Cynata Therapeutics Announces Change in Director’s Interest
TipRanks · 11/30/2025 23:27
Cynata Therapeutics Announces Change in Director’s Securities Interests
TipRanks · 11/30/2025 23:18
More
About CYYNF
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.

Webull offers Cynata Therapeutics Ltd stock information, including OTCPK: CYYNF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYYNF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYYNF stock methods without spending real money on the virtual paper trading platform.